Close Menu
Protagen, a Dortmund, Germany-based protein-array firm, has been selected to take part in a German government-funded consortium focused on biomarker discovery that in Protagen’s case will rely on its flagship UNIarray protein chip platform to study Alzheimer’s disease.
 
The consortium, called NeuroAllianz, is led by researchers at the University of Bonn and backed by an initial three-year, €20 million ($27 million) award from the German Federal Ministry of Research and Education, or BMBF.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

Feb
18
Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
25
Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.